Kelly Mabry

Cellia Science, Inc. develops and commercializes blood cell analyzers that provide rapid, actionable blood cell counts at the point of care. The company was founded in 2021 and is based in Fayetteville, AR. Cellia Science's lead device provides neutrophil and platelet counts for chemotherapy patients at risk of neutropenia and thrombocytopenia, using label-free deep-UV imaging technology exclusively licensed from a third party. The technology will be applied to additional diseases with significant unmet need in the future. Kelly Mabry has been the CEO of the company since 2022.

Cellia Science, Inc. develops and commercializes blood cell analyzers that provide rapid, actionable blood cell counts at the point of care. The company was founded in 2021 and is based in Fayetteville, AR. Cellia Science's lead device provides neutrophil and platelet counts for chemotherapy patients at risk of neutropenia and thrombocytopenia, using label-free deep-UV imaging technology exclusively licensed from a third party. The technology will be applied to additional diseases with significant unmet need in the future. Kelly Mabry has been the CEO of the company since 2022.

Cellia Science, Inc. develops and commercializes blood cell analyzers that provide rapid, actionable blood cell counts at the point of care. The company was founded in 2021 and is based in Fayetteville, AR. Cellia Science's lead device provides neutrophil and platelet counts for chemotherapy patients at risk of neutropenia and thrombocytopenia, using label-free deep-UV imaging technology exclusively licensed from a third party. The technology will be applied to additional diseases with significant unmet need in the future. Kelly Mabry has been the CEO of the company since 2022.